$KALV
KalVista Pharmaceuticals, Inc.

2019 Q4 Form 10-Q Financial Statement

#000156459020056718 Filed on December 10, 2020

View on sec.gov

Income Statement

Concept 2019 Q4
Revenue $3.920M
YoY Change -29.9%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.420M
YoY Change 31.03%
% of Gross Profit
Research & Development $9.790M
YoY Change 24.24%
% of Gross Profit
Depreciation & Amortization $130.0K
YoY Change 30.0%
% of Gross Profit
Operating Expenses $13.21M
YoY Change 25.98%
Operating Profit
YoY Change
Interest Expense $1.070M
YoY Change -3666.67%
% of Operating Profit
Other Income/Expense, Net $2.320M
YoY Change 43.21%
Pretax Income -$5.900M
YoY Change 78.79%
Income Tax
% Of Pretax Income
Net Earnings -$5.903M
YoY Change 78.66%
Net Earnings / Revenue -150.59%
Basic Earnings Per Share
Diluted Earnings Per Share -$331.1K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $93.50M
YoY Change -22.79%
Cash & Equivalents $21.72M
Short-Term Investments $71.70M
Other Short-Term Assets $2.600M
YoY Change 36.84%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $107.9M
YoY Change -17.06%
LONG-TERM ASSETS
Property, Plant & Equipment $4.000M
YoY Change 73.91%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $200.0K
YoY Change 0.0%
Total Long-Term Assets $4.200M
YoY Change 68.0%
TOTAL ASSETS
Total Short-Term Assets $107.9M
Total Long-Term Assets $4.200M
Total Assets $112.1M
YoY Change -15.46%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.200M
YoY Change -26.67%
Accrued Expenses $5.600M
YoY Change 86.67%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $10.50M
YoY Change -49.76%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $3.800M
YoY Change -19.15%
Total Long-Term Liabilities $3.800M
YoY Change -18.63%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.50M
Total Long-Term Liabilities $3.800M
Total Liabilities $14.30M
YoY Change -44.14%
SHAREHOLDERS EQUITY
Retained Earnings -$115.0M
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $97.79M
YoY Change
Total Liabilities & Shareholders Equity $112.1M
YoY Change -15.43%

Cashflow Statement

Concept 2019 Q4
OPERATING ACTIVITIES
Net Income -$5.903M
YoY Change 78.66%
Depreciation, Depletion And Amortization $130.0K
YoY Change 30.0%
Cash From Operating Activities -$7.810M
YoY Change -11.15%
INVESTING ACTIVITIES
Capital Expenditures -$110.0K
YoY Change -50.0%
Acquisitions
YoY Change
Other Investing Activities -$1.400M
YoY Change
Cash From Investing Activities -$1.510M
YoY Change 586.36%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 140.0K
YoY Change -99.83%
NET CHANGE
Cash From Operating Activities -7.810M
Cash From Investing Activities -1.510M
Cash From Financing Activities 140.0K
Net Change In Cash -9.180M
YoY Change -112.44%
FREE CASH FLOW
Cash From Operating Activities -$7.810M
Capital Expenditures -$110.0K
Free Cash Flow -$7.700M
YoY Change -10.15%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
170000
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
54000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11538000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-10814000
CY2020Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
338000
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-5000
CY2020Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
70000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
74435000
CY2020Q4 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
60000
CY2020Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1248000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
96738000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-7338000
CY2019Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-89000
CY2019Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
28000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
101867000
CY2019Q4 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
138000
CY2019Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1162000
CY2019Q4 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
28000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
97787000
us-gaap Profit Loss
ProfitLoss
-21241000
us-gaap Profit Loss
ProfitLoss
-13241000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
261000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
248000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2436000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2236000
us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
116000
us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
129000
kalv Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
17000
kalv Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
2000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
137000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
79000
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
168000
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
81000
kalv Increase Decrease In Research And Development Tax Credit Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable
-2322000
kalv Increase Decrease In Research And Development Tax Credit Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable
577000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3031000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-785000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
446000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-558000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1335000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-564000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-7289000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11540000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19089000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
19342000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
42561000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
31261000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
39729000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
35000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
212000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
11884000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3044000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
11422000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
106000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
106000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-65000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
308000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
385000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-10287000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
15789000
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
32006000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
16174000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
21719000
CY2020Q4 kalv Cash Cash Equivalents And Marketable Securities
CashCashEquivalentsAndMarketableSecurities
55900000
CY2020Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
1257000
CY2020Q4 kalv Cash And Cash Equivalents And Marketable Securities Fair Value Disclosure
CashAndCashEquivalentsAndMarketableSecuritiesFairValueDisclosure
40957000
CY2020Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
650000
CY2020Q2 kalv Cash And Cash Equivalents And Marketable Securities Fair Value Disclosure
CashAndCashEquivalentsAndMarketableSecuritiesFairValueDisclosure
52575000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
39517000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
220000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
37000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
39700000
CY2020Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
51456000
CY2020Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
470000
CY2020Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1000
CY2020Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
51925000
CY2020Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
25192000
CY2020Q4 kalv Available For Sale Securities Debt Maturities After One Through Two Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue
5817000
CY2020Q4 kalv Available For Sale Securities Debt Maturities After Two Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterTwoYearsFairValue
8691000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2952000
CY2020Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2333000
CY2020Q4 kalv Accrued Research Expense Current
AccruedResearchExpenseCurrent
3501000
CY2020Q2 kalv Accrued Research Expense Current
AccruedResearchExpenseCurrent
2821000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
410000
CY2020Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
173000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
78000
CY2020Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
128000
CY2020Q4 kalv Contractual Obligation Remaining Commitment Including Cancellation Provisions
ContractualObligationRemainingCommitmentIncludingCancellationProvisions
1800000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
297000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
390000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
245000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
149000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
149000
CY2020Q4 kalv Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
459000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1689000
CY2020Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
335000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1354000

Files In Submission

Name View Source Status
0001564590-20-056718-index-headers.html Edgar Link pending
0001564590-20-056718-index.html Edgar Link pending
0001564590-20-056718.txt Edgar Link pending
0001564590-20-056718-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
glqmtvrita2h000001.jpg Edgar Link pending
glqmtvrita2h000002.jpg Edgar Link pending
glqmtvrita2h000003.jpg Edgar Link pending
kalv-10q_20201031.htm Edgar Link pending
kalv-20201031.xml Edgar Link completed
kalv-20201031.xsd Edgar Link pending
kalv-20201031_cal.xml Edgar Link unprocessable
kalv-20201031_def.xml Edgar Link unprocessable
kalv-20201031_lab.xml Edgar Link unprocessable
kalv-20201031_pre.xml Edgar Link unprocessable
kalv-ex101_114.htm Edgar Link pending
kalv-ex311_8.htm Edgar Link pending
kalv-ex312_7.htm Edgar Link pending
kalv-ex321_6.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending